SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jeffbas who wrote (3070)5/27/1999 2:04:00 PM
From: BMcV  Read Replies (1) of 10280
 
One more thing. I compared SEPR to generic because I thought their eventual size might be similar to some of those companies, not because their business is the same. SEPR should be able to price at a premium, since they will have demonstrated benefits, protected by their patents. It's possible the benefits will be limited to a specific group of patients, eg, those who report restlessness after taking albuterol, which could limit the market. But SEPR should be able to maintain margins, even despite spending more on R&D.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News